- Following positive Phase 3 trial data, the FDA has approved Regeneron's (NASDAQ:REGN) Eylea for the treatment of diabetic macular edema (DME).
- Eylea is already available in the U.S. for the treatment of neovascular age-related macular degeneration and macular edema following central retinal vein occulusion, following 2011 and 2012 approvals.
- Europe's CHMP has given a positive opinion for approving Eylea for DME treatment, and regulatory submissions for DME treatment have also been made in Japan, Asia-Pac, and Latin America.
- REGN +3.1% AH.
- Prior Eylea coverage
FDA approves Regeneron's Eylea for DME treatment
Recommended For You
More Trending News
About REGN Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| REGN | - | - |
| Regeneron Pharmaceuticals, Inc. | ||